#90 Landmark Clinical Evidence
Peer-reviewed human research with direct implications for cannabis medicine practice.
The 2026 Utah legislature is expected to consider legislation addressing cannabis, psychedelics, and kratom, reflecting evolving attitudes toward these substances at the state level. Utah’s regulatory landscape remains restrictive compared to many states, with current law limiting cannabis access primarily to a narrow medical cannabis program, while psychedelics and kratom remain largely unregulated or prohibited. Any legislative changes could potentially expand patient access to cannabis for additional medical conditions or clarify regulatory status for emerging botanicals, though the conservative political environment suggests modifications will likely be incremental. For clinicians in Utah, awareness of forthcoming legislative developments is important because changes to state law would directly impact the conditions for which cannabis recommendations can be made and the counseling required when discussing these treatments with patients. Clinicians should monitor these legislative discussions closely, as new regulations could either broaden therapeutic options for patients with limited alternatives or create new compliance requirements for those currently recommending cannabis under existing medical programs. Staying informed about Utah’s legislative trajectory on cannabis and related substances will help clinicians anticipate changes to their practice environment and provide accurate guidance to patients about legal access and use.
💊 As Utah’s legislature considers regulatory frameworks for cannabis, psychedelics, and kratom in 2026, clinicians should recognize that legislative changes often precede robust clinical evidence and formal clinical guidelines, creating uncertainty in practice. The patchwork of state-level policies means that patients in Utah may have different access to these substances than those in neighboring states, potentially complicating discussions about evidence-based treatment options and creating confusion about legal versus medical status. While some cannabis compounds show promise for specific indications like chemotherapy-induced nausea or chronic pain, and psychedelics demonstrate emerging research in treatment-resistant depression and PTSD, the quality of products, dosing standardization, and long-term safety profiles remain inadequately characterized for most patient populations. Clinicians should stay informed about their state’s evolving regulations and maintain realistic conversations with patients about what current evidence actually supports, while documenting discussions about legal status separately from medical recommendations to protect both
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: